Unusual 11 Mid-Day Movers 1/9: PALM, HWAY, RAMS, AMMD Higher; RGN, WSCI, RMBS, OREX Lower Jan 9, 2009 12:51PM

RegeneRx Biopharma (AMEX: RGN) 43.4% LOWER; announced the outcome of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with chronic pressure ulcers. RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tβ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with no drug-related serious adverse events, which was the primary objective of the study. Regarding the secondary objective of the study, there were no statistically significant differences observed for complete wound healing or the rate of wound healing between the placebo group and any of the three RGN-137 dose levels. The mid-dose level ...